Search results (13)
« Back to NewsComparative analysis of ADO and PHD enzymes allows researchers to better understand their co-evolution and integration into oxygen homeostasis mechanisms
17 August 2023
Ludwig Oxford’s Peter Ratcliffe and Tom Keeley have undertaken a comparative analysis of a number of enzymes involved in the adaption of cells to oxygen level changes.
HIF and AHR transcription factors interact in kidney carcinomas raising the potential for effective combination therapy
6 February 2023
Ludwig Oxford’s David Mole and Peter Ratcliffe show interaction between transcription factors HIF and AHR, indicating a combined approach to therapy may provide greater efficacy for cancer treatment.
Ludwig’s Tammie Bishop awarded Associate Professorship
10 January 2023
Congratulations to Tammie Bishop, who is made associate professor at the University of Oxford.
Pan-cancer gene signature provides insights into HIF pathway activation
29 November 2022
Researchers from David Mole’s and Peter Ratcliffe’s laboratories establish a HIF metagene for studying hypoxia pathways.
Dr Tammie Bishop receives The Physiology Society’s R Jean Banister Prize
17 August 2022
Congratulations to Dr Tammie Bishop who will give the R Jean Banister Prize Lecture Series in 2023
Ludwig Oxford retreat 2022 – a recap
15 July 2022
Barnes Boccellato Byrne Constantinescu De Val Goding Kriaucionis Lu Mehdipour Moura Alves Ratcliffe Schuster-Böckler Shi Song Van den Eynde
On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.
Ludwig Oxford at AACR 2022
8 April 2022
Several Ludwig Oxford researchers present at the American Association for Cancer Research (AACR) Annual Meeting.
Developmental origins of inherited cancers bearing mutations in the oxygen-sensing pathway
19 October 2021
Dr Tammie Bishop’s and Professor Sir Peter Ratcliffe’s groups shed light on the developmental origins of inherited cancers with mutations in the HIF pathway.
HIFs inhibit SARS-CoV-2 infection of lung epithelial cells
7 April 2021
Activation of hypoxia inducible factors (HIFs) by either hypoxia or drug treatment inhibits SARS-CoV-2 entry and replication in lung epithelial cells, raising the potential of using clinically licensed HIF activators to prevent and/or treat COVID-19.
Anti-cancer HIF-2 inhibition affects the hypoxic ventilatory response
31 January 2020
Researchers from Dr Tammie Bishop’s and Prof Sir Peter Ratcliffe’s laboratories show that an anti-cancer HIF inhibitor impairs the normal ventilatory response to low oxygen.
Support for the pathway tuning model of cancer
23 December 2019
Researchers from David Mole’s and Peter Ratcliffe’s labs investigate a model for cancer evolution using renal clear cell carcinoma.
Nobel Prize 2019 awarded to Sir Peter Ratcliffe
10 December 2019
Ludwig Oxford’s Professor Sir Peter Ratcliffe receives the Nobel Prize in physiology or medicine at an awards ceremony in Stockholm.
Ludwig Oxford’s Sir Peter Ratcliffe wins the Nobel Prize in medicine
7 October 2019
Peter Ratcliffe shares the prize with William Kaelin of the Dana-Farber Cancer Institute and Gregg Semenza of John Hopkins University for their research on cellular responses to hypoxia.